1. Desmoplasia and Chemoresistance in Pancreatic Cancer
- Author
-
Ralf Jesenofsky, Stephan L. Haas, Cornelius Weidenauer, Wolfgang Hagmann, J.-Matthias Löhr, Ralf Faissner, Rainer Heuchel, Patrick Michl, and Marvin Schober
- Subjects
Oncology ,cancer stem cells ,Cancer Research ,medicine.medical_specialty ,Pathology ,Stromal cell ,pancreatic cancer ,Review ,Drug resistance ,de novo resistance ,lcsh:RC254-282 ,Cancer stem cell ,Pancreatic cancer ,Internal medicine ,CAM-DR ,medicine ,SFM-DR ,drug resistance ,business.industry ,desmoplasia ,Mortality rate ,Cancer ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,matrix ,Desmoplasia ,future therapies ,Cancer cell ,medicine.symptom ,business - Abstract
Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of age. Although great strides have been taken in treating PDAC over the past decades its incidence nearly equals its mortality rate and it was quoted as the 4th leading cause of cancer deaths in the U.S. in 2012. This review aims to focus on research models and scientific developments that help to explain the extraordinary resistance of PDAC towards current therapeutic regimens. Furthermore, it highlights the main features of drug resistance including mechanisms promoted by cancer cells or cancer stem cells (CSCs), as well as stromal cells, and the acellular components surrounding the tumor cells—known as peritumoral desmoplasia—that affects intra-tumoral drug delivery. Finally, therapeutic concepts and avenues for future research are suggested, based on the topics discussed.
- Published
- 2014